Physician profile
Michael L Bowlin
NPI 1154560225
$6,545.43
in general payments reported to CMS, 2019-2025
41 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $425 · 2021: $1,104 · 2022: $1,425 · 2023: $1,537 · 2024: $1,186 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,247.29 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $617.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $465.76 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $350.51 | 2020-2025 | |
| Astellas Pharma US INC | $334.18 | 2020-2025 | Veozah, Myrbetriq |
| Amgen INC. | $325.03 | 2020-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.43 | 2020-2024 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $278.14 | 2019-2021 | |
| Abbott Laboratories | $262.21 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $248.84 | 2021-2025 | Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $181.26 | 2019-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $169.73 | 2020-2023 | |
| Supernus Pharmaceuticals, INC. | $138.14 | 2021-2023 | Qelbree |
| Sumitomo Pharma America, INC. | $124.76 | 2023-2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $116.60 | 2023-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bowlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.